Nebenwirkungen · Briumvi
Briumvi 150 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-150195 · Präparat HOS-100264
In active-controlled RMS trials, treatment with ublituximab resulted in a decrease in total immunoglobulins over the controlled period of the studies, mainly driven by the reduction in IgM. The proportion of patients at baseline reporting IgG, IgA, and IgM below the lower limit of normal (LLN) in ublituximab treated patients was 6.3%, 0.6%, and 1.1%, respectively. Following treatment, the proportion of ublituximab treated patients reporting IgG, IgA, and IgM below the LLN at 96 weeks was 6.5%, 2.4%, and 20.9%, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-08T16:12:00Z · SHA-256 53c5ab94f9975d70ba11f2528f2ff97b611a29e4dee6edabccf82093c0699947 · Passage d2e87565832584bd4b01785b436ac74766c4e72d954a0b4394774cfe891c5c59 · Zeichen 3062–3591 im Abschnitt